Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation

NEXT STORY
Summit Highlights Discovery of New Mechanism Antibiotics for the Treatment of Gonorrhoea at ECCMID 2018
PREV STORY
BriaCell Activates A Clinical Site in Florida for Phase IIa Study of its Lead Candidate in Advanced Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

EDAP to Hold Third Quarter 2015 Conference Call on November 19, 2015

LYON, France, Nov. 12, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global ...

author_avatar
NASDAQ Market News

Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth

MORRIS PLAINS, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or ...

author_avatar
NASDAQ Market News

Athenex, Inc. Announces Second Quarter 2017 Results

Received Chinese FDA approval to begin clinical trials of KX-02 Tablet for GlioblastomaBegan patient ...

author_avatar
NASDAQ Market News